Facial Skin ConditionNCT07723508
BeauSaki Bird's Nest Peptide Efficacy
A study testing BeauSaki Edible Bird's Nest Peptide Product in people with Facial Skin Condition, run by Chia Nan University of Pharmacy ＆ Science at 1 site in Taiwan.
Trial summary
The goal of this clinical trial is to learn whether BeauSaki Edible Bird's Nest Peptide Product can improve facial skin conditions in healthy adult participants. The main questions it aims to answer are: Can daily intake of the edible bird's nest peptide product improve facial skin hydration, elasticity, brightness… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Facial Skin Condition
- What is being tested?
- BeauSaki Edible Bird's Nest Peptide Product
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Oct 2025to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants aged over 18 years.
Who cannot join
- Individuals who are unwilling to participate voluntarily.
- Individuals diagnosed by a physician with skin disease, liver cirrhosis, or chronic renal failure.
- Individuals with known allergies to cosmetics, drugs, or foods.
- Pregnant or breastfeeding individuals.
- Individuals taking medications for chronic diseases.
- Students taught by the principal investigator.
- Individuals unwilling to allow their study-related photographs to be disclosed. Vegetarians.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy Evaluation of BeauSaki Edible Bird's Best Peptide Product
The goal of this clinical trial is to learn whether BeauSaki Edible Bird's Nest Peptide Product can improve facial skin conditions in healthy adult participants. The main questions it aims to answer are:
Can daily intake of the edible bird's nest peptide product improve facial skin hydration, elasticity, brightness, wrinkles, pores, spots, redness, and skin texture after 8 weeks?
Read more
Is the edible bird's nest peptide product well tolerated by participants during the study period?
Researchers will compare participants who take the edible bird's nest peptide capsule with participants who take a placebo capsule without edible bird's nest to see if the product improves facial skin conditions.
Participants will:
- Take one capsule daily for 8 weeks.
- Visit the study site at baseline, week 4, and week 8 for non-invasive facial skin assessments.
- Cleanse their face with water and rest under room temperature conditions for 30 minutes before each skin assessment.
- Complete a brief questionnaire about perceived skin condition and product satisfaction at baseline, week 4, and week 8.
- Have facial photographs taken for skin condition evaluation, with identifiable areas masked before disclosure.
- Conditions
- Facial Skin Condition
- Being tested
- BeauSaki Edible Bird's Nest Peptide Product, Placebo Capsule (matched dosing schedule)
- Keywords
- Skin Hydration, Skin Elasticity, Skin Brightness, Transepidermal Water Loss, Wrinkles, Skin Texture
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BeauSaki Edible Bird's Nest Peptide ProductDietary supplement
Participants will take one capsule daily for 8 weeks.
Placebo Capsule (matched dosing schedule)Dietary supplement
Participants will take one placebo capsule without edible bird's nest daily for 8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| BeauSaki Edible Bird's Nest Peptide Group | Experimental | Participants in this group will take one capsule of BeauSaki Edible Bird's Nest Peptide Product daily for 8 weeks. Receives: Dietary Supplement: BeauSaki Edible Bird's Nest Peptide Product |
| Placebo Group | Placebo comparator | Participants in this group will take one placebo capsule without edible bird's nest daily for 8 weeks. Receives: Dietary Supplement: Placebo Capsule (matched dosing schedule) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Facial Skin Analysis Parameters
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots, wrinkles, texture, pores, UV spots, brown Spots, red areas, porphyrins.
Units: arbitrary units. Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8.
Measured: Baseline, week 4, and week 8
Skin Moisture
Skin moisture meter (VapoMeter) was utilized to measure skin moisture. Units: g/m²h Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8.
Measured: Baseline, week 4, and week 8
Skin elasticity
Skin elastometer (Soft Plus) was utilized to measure skin elasticity. Units: arbitrary units. Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8.
Measured: Baseline, week 4, and week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2026
- Study start1 Oct 2025
- Primary completion31 Jan 2026
- Study completion31 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Facial Skin ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chia Nan University of Pharmacy ＆ Science
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07723508
- Sponsor's protocol ID
- TMSHIRB25-104-B
- Status last verified
- Jul 2026
- First submitted
- 9 Jul 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy Evaluation of BeauSaki Edible Bird's Best Peptide Product
- ClinicalTrials.gov ID
- NCT07723508
- Acronym / sponsor ID
- TMSHIRB25-104-B
- Conditions
- Facial Skin Condition
- Keywords
- Skin Hydration, Skin Elasticity, Skin Brightness, Transepidermal Water Loss, Wrinkles, Skin Texture
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Chia Nan University of Pharmacy ＆ ScienceUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 31 Jan 2026 (actual)
- Study completion
- 31 Mar 2026 (actual)
- First posted
- 23 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether BeauSaki Edible Bird's Nest Peptide Product can improve facial skin conditions in healthy adult participants. The main questions it aims to answer are:
Can daily intake of the edible bird's nest peptide product improve facial skin hydration, elasticity, brightness, wrinkles, pores, spots, redness, and skin texture after 8 weeks?
Is the edible bird's nest peptide product well tolerated by participants during the study period?
Researchers will compare participants who take the edible bird's nest peptide capsule with participants who take a placebo capsule without edible bird's nest to see if the product improves facial skin conditions.
Participants will:
- Take one capsule daily for 8 weeks.
- Visit the study site at baseline, week 4, and week 8 for non-invasive facial skin assessments.
- Cleanse their face with water and rest under room temperature conditions for 30 minutes before each skin assessment.
- Complete a brief questionnaire about perceived skin condition and product satisfaction at baseline, week 4, and week 8.
- Have facial photographs taken for skin condition evaluation, with identifiable areas masked before disclosure.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BeauSaki Edible Bird's Nest Peptide Group | Experimental | Dietary Supplement: BeauSaki Edible Bird's Nest Peptide ProductParticipants in this group will take one capsule of BeauSaki Edible Bird's Nest Peptide Product daily for 8 weeks. |
| Placebo Group | Placebo comparator | Dietary Supplement: Placebo Capsule (matched dosing schedule)Participants in this group will take one placebo capsule without edible bird's nest daily for 8 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Participants aged over 18 years.
Key exclusion criteria (7 listed)
- Individuals who are unwilling to participate voluntarily.
- Individuals diagnosed by a physician with skin disease, liver cirrhosis, or chronic renal failure.
- Individuals with known allergies to cosmetics, drugs, or foods.
- Pregnant or breastfeeding individuals.
- Individuals taking medications for chronic diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BeauSaki Edible Bird's Nest Peptide ProductParticipants will take one capsule daily for 8 weeks. | Dietary supplement | BeauSaki Edible Bird's Nest Peptide Group |
| Placebo Capsule (matched dosing schedule)Participants will take one placebo capsule without edible bird's nest daily for 8 weeks. | Dietary supplement | Placebo Group |
Primary outcome
Facial Skin Analysis Parameters
Time frame: Baseline, week 4, and week 8
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots, wrinkles, texture, pores, UV spots, brown Spots, red areas, porphyrins. Units: arbitrary units. Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8.
Skin Moisture
Time frame: Baseline, week 4, and week 8
Skin moisture meter (VapoMeter) was utilized to measure skin moisture. Units: g/m²h Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8.
Skin elasticity
Time frame: Baseline, week 4, and week 8
Skin elastometer (Soft Plus) was utilized to measure skin elasticity. Units: arbitrary units. Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Facial Skin Condition
RecruitingPhase 3
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
Vitiligo, Non-Segmental Vitiligo (NSV)
Enrolling by invitationPhase 2/3
A Split-Face Comparative Study of Mono Threads Versus Combination With Plasma Gel for the Treatment of Post-Acne Scars
Acne
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruiting
The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen and MSM on Facial Erythema and Other Skin Parameters
Erythema, Telangiectasis
Enrolling by invitationPhase 4
Microneedling-Assisted Metformin, Tranexamic Acid, and Modified Kligman's Formula for Melasma
Melasma (Facial Melasma)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BeauSaki Edible Bird's Nest Peptide Product in people with Facial Skin Condition, run by Chia Nan University of Pharmacy ＆ Science at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Facial Skin Analysis Parameters (time frame: Baseline, week 4, and week 8). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.